comparemela.com

Latest Breaking News On - Arthex biotech - Page 1 : comparemela.com

Myotonic Dystrophy Pipeline Assessment 2024 | In-Depth Insights Into The Emerging Drugs, Latest FDA Approvals, Clinical Trials, Ter, Key Companies

Myotonic Dystrophy Pipeline Assessment 2024 | In-Depth Insights Into The Emerging Drugs, Latest FDA Approvals, Clinical Trials, Ter, Key Companies
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Nexien biopharmaCompanies in myotonic dystrophy therapeutics marketLocana incRoute of administrationDrug administrationAdministration roPepgen corporationKey companiesSyros pharmaceuticalsDystrophy pipelineMyotonic dystrophy marketHarmony biosciencesAvidity biosciencesDyne therapeuticsEntrada therapeuticsArthex biotech

ARTHEx Biotech Announces Oral Presentation on ATX-01 at the Oligonucleotide & Peptide Therapeutics (TIDES) Conference 2024

/PRNewswire/ ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs,.

United statesJuniper pointAmy conradCompany contactPeptide therapeuticsBiotech executive chairmanSkeletal muscleNervous systemDual therapeutic approachOligonucleotide discoveryOrphan drug designationMyotonic dystrophy typeArthex biotechHealth care amp hospitalsMedical pharmaceuticalsClinical trials amp medical discoveries

ARTHEx Biotech Announces Participation at the 23rd Annual Needham Virtual Healthcare Conference

/PRNewswire/ ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs,.

Amy conradCompany contactNeedham virtual healthcare conferenceArthex biotech

ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)

/PRNewswire/ ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs,.

Amy conradJudith walkerNicholas johnsonVirginia commonwealth universityDepartment of neurologyDrug administrationCompany contactMyotonic dystrophy typeChief medical officerVice chairOrphan drug designationArthex biotech

Norway-based Hadean Ventures announces oversubscribed final close of Hadean Capital II

Norway-based Hadean Ventures announces oversubscribed final close of Hadean Capital II
arcticstartup.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from arcticstartup.com Daily Mail and Mail on Sunday newspapers.

Ingrid teigland akayEli lillyTapio passinenWalter stockingerHadean venturesHadean capitalKfw capitalAlex therapeuticsArthex biotechComplement therapeuticsEmergence therapeuticsRibbon biolabsTeigland akayManaging partnerHadean ventureInvestment director

vimarsana © 2020. All Rights Reserved.